Saturday, June 18, 2016 9:12:32 PM
"Illustrative Net earnings at $15 US sales
$15 million US in sales will probably be achieved without the recent mega deal with the US's largest private healthcare technology provider.
Several contracts were recently signed which should lead to a rapid expansion of sales outside the US and EU.
Those are the two largest healthcare regions of the world.
So, lets take $15 million US in sales as being certainly achievable over the next 4 quarters..
Thats about $20 million cad or about 3 times the annualized 2016 sales todate.
Gross margins at very modest sales are already 65 %.
As sales expand, economies of scale will move gross margin upwards.
I shall use GM=70 %.
That is, operating earnings from $20 million cad in sales will be about $14 million.
Annualized operating costs are about $5.5 million in 2016 todate.
I will boost this by 30 % which should easily account for expanded G & A @ $20 million in sales.
So, total operating costs will be about $ 7 million which means that Ebitda will be about $ 7 million or about $0.35 per share.
COV have tax loss pools to protect early profits but lets assume that they pay the full income tax of 26 %.
The computations are elementary.
Net earnings will be about $5.5 million cad or about $0.26 per fd share.
If you check out healthcare technology/device ETFs, you will find that they trade over 30 times net earnings.
With a pristine balance sheet without debt, COV should qualify for at least 20 times net earnings, if not higher.
This implies a realistic fair value above $5 per fd share @ very achievable annual sales of $20 million cad.
My own view is that within 2 years, Covalon will have annual sales several multiples hgher than $20 million.
Hence the magnificant upside here for the astute investor who buys and holds for the next 2 years..
Illustrative Net earnings at $15 US sales
$15 million US in sales will probably be achieved without the recent mega deal with the US's largest private healthcare technology provider.
Several contracts were recently signed which should lead to a rapid expansion of sales outside the US and EU.
Those are the two largest healthcare regions of the world.
So, lets take $15 million US in sales as being certainly achievable over the next 4 quarters..
Thats about $20 million cad or about 3 times the annualized 2016 sales todate.
Gross margins at very modest sales are already 65 %.
As sales expand, economies of scale will move gross margin upwards.
I shall use GM=70 %.
That is, operating earnings from $20 million cad in sales will be about $14 million.
Annualized operating costs are about $5.5 million in 2016 todate.
I will boost this by 30 % which should easily account for expanded G & A @ $20 million in sales.
So, total operating costs will be about $ 7 million which means that Ebitda will be about $ 7 million or about $0.35 per share.
COV have tax loss pools to protect early profits but lets assume that they pay the full income tax of 26 %.
The computations are elementary.
Net earnings will be about $5.5 million cad or about $0.26 per fd share.
If you check out healthcare technology/device ETFs, you will find that they trade over 30 times net earnings.
With a pristine balance sheet without debt, COV should qualify for at least 20 times net earnings, if not higher.
This implies a realistic fair value above $5 per fd share @ very achievable annual sales of $20 million cad.
My own view is that within 2 years, Covalon will have annual sales several multiples hgher than $20 million.
Hence the magnificant upside here for the astute investor who buys and holds for the next 2 years..
Read more at http://www.stockhouse.com/companies/bullboard/v.cov/covalon-technologies-ltd#Ibr7J2jWEm544puP.99
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM